Exact Mass: 421.1305
Exact Mass Matches: 421.1305
Found 458 metabolites which its exact mass value is equals to given mass value 421.1305
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Topotecan
Topotecan is only found in individuals that have used or taken this drug. It is an antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. [PubChem]Topotecan has the same mechanism of action as irinotecan and is believed to exert its cytotoxic effects during the S-phase of DNA synthesis. Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. This ternary complex interferes with the moving replication fork, which leads to the induction of replication arrest and lethal double-stranded breaks in DNA. As mammalian cells cannot efficiently repair these double strand breaks, the formation of this ternary complex eventually leads to apoptosis (programmed cell death).Topotecan mimics a DNA base pair and binds at the site of DNA cleavage by intercalating between the upstream (−1) and downstream (+1) base pairs. Intercalation displaces the downstream DNA, thus preventing religation of the cleaved strand. By specifically binding to the enzyme–substrate complex, Topotecan acts as an uncompetitive inhibitor. Topotecan is a pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks. It has a role as an EC 5.99.1.2 (DNA topoisomerase) inhibitor and an antineoplastic agent. An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. Topotecan is a Topoisomerase Inhibitor. The mechanism of action of topotecan is as a Topoisomerase Inhibitor. Topotecan is a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I. See also: Topotecan Hydrochloride (active moiety of). L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01C - Plant alkaloids and other natural products > L01CE - Topoisomerase 1 (top1) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059004 - Topoisomerase I Inhibitors C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors Same as: D08618 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Pitavastatin
Most statins are metabolised in part by one or more hepatic cytochrome P450 enzymes, leading to an increased potential for drug interactions and problems with certain foods (such as grapefruit juice). Pitavastatin appears to be a substrate of CYP2C9, and not CYP3A4 (which is a common source of interactions in other statins). As a result, pitavastatin is less likely to interact with drugs that are metabolized via CYP3A4, which might be important for elderly patients who need to take multiple medicines. Pitavastatin (usually as a calcium salt) is a member of the medication class of statins, marketed in the United States under the trade name Livalo. Like other statins, it is an inhibitor of HMG-CoA reductase, the enzyme that catalyses the first step of cholesterol synthesis. It has been available in Japan since 2003, and is being marketed under licence in South Korea and in India. It is likely that pitavastatin will be approved for use in hypercholesterolaemia (elevated levels of cholesterol in the blood) and for the prevention of cardiovascular disease outside South and Southeast Asia as well. C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects[1][2][3][8].
5-O-p-Coumaroylnigrumin
5-O-p-Coumaroylnigrumin is found in fruits. 5-O-p-Coumaroylnigrumin is a constituent of the seeds of Ribes nigrum (blackcurrant). Constituent of the seeds of Ribes nigrum (blackcurrant). 5-O-p-Coumaroylnigrumin is found in fruits.
3-(6-Methylpyridin-2-yl)-N-phenyl-4-(quinolin-4-yl)-1H-pyrazole-1-carbothioamide
(3R,5S)-7-[2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid
Mosapride
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03F - Propulsives > A03FA - Propulsives D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D005765 - Gastrointestinal Agents
Hyzetimibe
Mosapride
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03F - Propulsives > A03FA - Propulsives D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D005765 - Gastrointestinal Agents
(3S,4R)-4-(5,7-dihydroxy-2-methyl-4-oxo-4H-1-benzopyran-8-yl)piperidin-3-yl (2E)-3-phenylprop-2-enoate|chrotacumine F
(2S)-2-{[6-O-(beta-D-glucopyranosyl)-beta-D-glucopyranosyl]oxy}-3-methylbut-3-enenitrile|proacacipetalin 6?-O-b-d-glucopyranoside
1D-6-O-(2-amino-2-deoxy-alpha-D-glucopyranosyl)-chiro-inositol 1-phosphate
3-(4-Methyl-thiazol-2-yl)-7-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-chromen-4-one
Pitavastatin
C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects[1][2][3][8].
Topotecan
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01C - Plant alkaloids and other natural products > L01CE - Topoisomerase 1 (top1) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059004 - Topoisomerase I Inhibitors C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Piragliatin
CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3431; ORIGINAL_PRECURSOR_SCAN_NO 3429 C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3421; ORIGINAL_PRECURSOR_SCAN_NO 3418 CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3414; ORIGINAL_PRECURSOR_SCAN_NO 3413 CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3421; ORIGINAL_PRECURSOR_SCAN_NO 3419 CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3430; ORIGINAL_PRECURSOR_SCAN_NO 3428 CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7552; ORIGINAL_PRECURSOR_SCAN_NO 7548 CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7558; ORIGINAL_PRECURSOR_SCAN_NO 7553 INTERNAL_ID 985; CONFIDENCE standard compound; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7580; ORIGINAL_PRECURSOR_SCAN_NO 7576 CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7580; ORIGINAL_PRECURSOR_SCAN_NO 7576 CONFIDENCE standard compound; INTERNAL_ID 985; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7590; ORIGINAL_PRECURSOR_SCAN_NO 7586
Ala Cys Asp Asn
Ala Cys Asn Asp
Ala Cys Gln Thr
Ala Cys Thr Gln
Ala Asp Cys Asn
Ala Asp Asn Cys
Ala Met Asn Ser
Ala Met Ser Asn
Ala Asn Cys Asp
Ala Asn Asp Cys
Ala Asn Met Ser
Ala Asn Ser Met
Ala Gln Cys Thr
Ala Gln Thr Cys
Ala Ser Met Asn
Ala Ser Asn Met
Ala Thr Cys Gln
Ala Thr Gln Cys
Cys Ala Asp Asn
Cys Ala Asn Asp
Cys Ala Gln Thr
Cys Ala Thr Gln
Cys Asp Ala Asn
Cys Asp Gly Lys
Cys Asp Gly Gln
Cys Asp Lys Gly
Cys Asp Asn Ala
Cys Asp Gln Gly
Cys Glu Gly Asn
Cys Glu Asn Gly
Cys Gly Asp Lys
Cys Gly Asp Gln
Cys Gly Glu Asn
Cys Gly Gly Trp
Cys Gly Lys Asp
Cys Gly Asn Glu
Cys Gly Gln Asp
Cys Gly Arg Ser
Cys Gly Ser Arg
Cys Gly Trp Gly
Cys Lys Asp Gly
Cys Lys Gly Asp
Cys Asn Ala Asp
Cys Asn Asp Ala
Cys Asn Glu Gly
Cys Asn Gly Glu
Cys Asn Ser Val
Cys Asn Val Ser
Cys Gln Ala Thr
Cys Gln Asp Gly
Cys Gln Gly Asp
Cys Gln Thr Ala
Cys Arg Gly Ser
Cys Arg Ser Gly
Cys Ser Gly Arg
Cys Ser Asn Val
Cys Ser Arg Gly
Cys Ser Val Asn
Cys Thr Ala Gln
Cys Thr Gln Ala
Cys Val Asn Ser
Cys Val Ser Asn
Cys Trp Gly Gly
Asp Ala Cys Asn
Asp Ala Asn Cys
Asp Cys Ala Asn
Asp Cys Gly Lys
Asp Cys Gly Gln
Asp Cys Lys Gly
Asp Cys Asn Ala
Asp Cys Gln Gly
Asp Gly Cys Lys
Asp Gly Cys Gln
Asp Gly Lys Cys
Asp Gly Gln Cys
Asp Lys Cys Gly
Asp Lys Gly Cys
Asp Asn Ala Cys
Asp Asn Cys Ala
Asp Asn Ser Ser
Asp Gln Cys Gly
Asp Gln Gly Cys
Asp Ser Asn Ser
Asp Ser Ser Asn
Glu Cys Gly Asn
Glu Cys Asn Gly
Glu Gly Cys Asn
Glu Gly Asn Cys
Glu Asn Cys Gly
Glu Asn Gly Cys
Gly Cys Asp Lys
Gly Cys Asp Gln
Gly Cys Glu Asn
Gly Cys Gly Trp
Gly Cys Lys Asp
Gly Cys Asn Glu
Gly Cys Gln Asp
Gly Cys Arg Ser
Gly Cys Ser Arg
Gly Cys Trp Gly
Gly Asp Cys Lys
Gly Asp Cys Gln
Gly Asp Lys Cys
Gly Asp Gln Cys
Gly Glu Cys Asn
Gly Glu Asn Cys
Gly Gly Cys Trp
Gly Gly Trp Cys
Gly Lys Cys Asp
Gly Lys Asp Cys
Gly Met Asn Thr
Gly Met Gln Ser
Gly Met Ser Gln
Gly Met Thr Asn
Gly Asn Cys Glu
Gly Asn Glu Cys
Gly Asn Met Thr
Gly Asn Thr Met
Gly Gln Cys Asp
Gly Gln Asp Cys
Gly Gln Met Ser
Gly Gln Ser Met
Gly Arg Cys Ser
Gly Arg Ser Cys
Gly Ser Cys Arg
Gly Ser Met Gln
Gly Ser Gln Met
Gly Ser Arg Cys
Gly Thr Met Asn
Gly Thr Asn Met
Gly Trp Cys Gly
Gly Trp Gly Cys
Lys Cys Asp Gly
Lys Cys Gly Asp
Lys Asp Cys Gly
Lys Asp Gly Cys
Lys Gly Cys Asp
Lys Gly Asp Cys
Met Ala Asn Ser
Met Ala Ser Asn
Met Gly Asn Thr
Met Gly Gln Ser
Met Gly Ser Gln
Met Gly Thr Asn
Met Asn Ala Ser
Met Asn Gly Thr
Met Asn Ser Ala
Met Asn Thr Gly
Met Gln Gly Ser
Met Gln Ser Gly
Met Ser Ala Asn
Met Ser Gly Gln
Met Ser Asn Ala
Met Ser Gln Gly
Met Thr Gly Asn
Met Thr Asn Gly
Asn Ala Cys Asp
Asn Ala Asp Cys
Asn Ala Met Ser
Asn Ala Ser Met
Asn Cys Ala Asp
Asn Cys Asp Ala
Asn Cys Glu Gly
Asn Cys Gly Glu
Asn Cys Ser Val
Asn Cys Val Ser
Asn Asp Ala Cys
Asn Asp Cys Ala
Asn Asp Ser Ser
Asn Glu Cys Gly
Asn Glu Gly Cys
Asn Gly Cys Glu
Asn Gly Glu Cys
Asn Gly Met Thr
Asn Gly Thr Met
Asn Met Ala Ser
Asn Met Gly Thr
Asn Met Ser Ala
Asn Met Thr Gly
Asn Ser Ala Met
Asn Ser Cys Val
Asn Ser Asp Ser
Asn Ser Met Ala
Asn Ser Ser Asp
Asn Ser Val Cys
Asn Thr Gly Met
Asn Thr Met Gly
Asn Val Cys Ser
Asn Val Ser Cys
Gln Ala Cys Thr
Gln Ala Thr Cys
Gln Cys Ala Thr
Gln Cys Asp Gly
Gln Cys Gly Asp
Gln Cys Thr Ala
Gln Asp Cys Gly
Gln Asp Gly Cys
Gln Gly Cys Asp
Gln Gly Asp Cys
Gln Gly Met Ser
Gln Gly Ser Met
Gln Met Gly Ser
Gln Met Ser Gly
Gln Ser Gly Met
Gln Ser Met Gly
Gln Thr Ala Cys
Gln Thr Cys Ala
Arg Cys Gly Ser
Arg Cys Ser Gly
Arg Gly Cys Ser
Arg Gly Ser Cys
Arg Ser Cys Gly
Arg Ser Gly Cys
Ser Ala Met Asn
Ser Ala Asn Met
Ser Cys Gly Arg
Ser Cys Asn Val
Ser Cys Arg Gly
Ser Cys Val Asn
Ser Asp Asn Ser
Ser Asp Ser Asn
Ser Gly Cys Arg
Ser Gly Met Gln
Ser Gly Gln Met
Ser Gly Arg Cys
Ser Met Ala Asn
Ser Met Gly Gln
Ser Met Asn Ala
Ser Met Gln Gly
Ser Asn Ala Met
Ser Asn Cys Val
Ser Asn Asp Ser
Ser Asn Met Ala
Ser Asn Ser Asp
Ser Asn Val Cys
Ser Gln Gly Met
Ser Gln Met Gly
Ser Arg Cys Gly
Ser Arg Gly Cys
Ser Ser Asp Asn
Ser Ser Asn Asp
Ser Val Cys Asn
Ser Val Asn Cys
Thr Ala Cys Gln
Thr Ala Gln Cys
Thr Cys Ala Gln
Thr Cys Gln Ala
Thr Gly Met Asn
Thr Gly Asn Met
Thr Met Gly Asn
Thr Met Asn Gly
Thr Asn Gly Met
Thr Asn Met Gly
Thr Gln Ala Cys
Thr Gln Cys Ala
Val Cys Asn Ser
Val Cys Ser Asn
Val Asn Cys Ser
Val Asn Ser Cys
Val Ser Cys Asn
Val Ser Asn Cys
Trp Cys Gly Gly
Trp Gly Cys Gly
Trp Gly Gly Cys
5-O-p-Coumaroylnigrumin
2-([4-(2-Chlorophenyl)-5-methoxycarbonyl-3-ethoxycarbonyl-6-methyl-2-pyridyl]methoxyacetic acid
4-(4-CHLORO-PHENYL)-3-METHYL-1-PHENYL-1H-INDENO[1,2-B]PYRAZOLO[4,3-E]PYRIDIN-5-ONE
Chlorotripyrrolidinophosphonium hexafluorophosphate
3-(4-CHLORO-PHENYL)-2-(9H-FLUOREN-9-YLMETHOXYCARBONYLAMINO)-PROPIONIC ACID
2-[[4-[ethyl(2-phenoxyethyl)amino]phenyl]azo]-5-nitro-3-Thiophenecarbonitrile
4-Chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-piperidinylidene]benzenesulfonamide
Choline Fenofibrate
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent > C98150 - Fibrate Antilipidemic Agent C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AB - Fibrates
Fmoc-(R)-3-Amino-3-(2-chloro-phenyl)-propionic acid
fmoc-(r)-3-amino-3-(3-chloro-phenyl)-propionic acid
1-{3-Isopropoxy-5-[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3- yl]phenyl}methanamine
fmoc-(s)-3-amino-3-(2-chloro-phenyl)-propionic acid
Spiro[7H-benzo[c]xanthene-7,1(3H)-isobenzofuran]-3-one,10-(diethylamino)-
fmoc-(s)-3-amino-3-(3-chloro-phenyl)-propionic acid
(3R,5R,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic acid
(3S,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic acid
(E,3S,5R)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid
Methylbenactyzium Bromide
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Methylbenactyzium Bromide is a muscarinic acetylcholine receptor (mAChR) inhibitor.
Rucaparib phosphate
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C62554 - Poly (ADP-Ribose) Polymerase Inhibitor D000970 - Antineoplastic Agents > D000067856 - Poly(ADP-ribose) Polymerase Inhibitors D004791 - Enzyme Inhibitors C471 - Enzyme Inhibitor
tert-Butyl 6-bromo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate
tert-Butyl 4-bromo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate
9-(diethylamino)spiro[2-benzofuran-3,12-benzo[a]xanthene]-1-one
3-benzhydrylsulfanyl-2-phenylmethoxycarbonylamino-propanoic acid
BENZYL ((1R,2S)-1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-1-HYDROXYPROPAN-2-YL)CARBAMATE
Sonedenoson
C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent
4-[3-(4-Chlorophenoxy)benzyl]-N-phenyl-1-piperazinecarboxamide
3-acetamido-6-acetyl-2-nitrophenyl 4-(dimethylamino)-3,5-difluorobenzoate
2-({(5R)-2-Oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-1H-isoindole-1,3(2H)-dione
(3R,5R,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic Acid CalciuM Salt
CCT251545
2-[[(5S)-2-Oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-1H-isoindole-1,3(2H)-dione
Dezapelisib
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
N-[2-methyl-5-[2-oxo-9-(1H-pyrazol-4-yl)-1-benzo[h][1,6]naphthyridinyl]phenyl]-2-propenamide
2-[(4-Chlorophenyl)methyl]-3-(4-methoxyphenyl)-1-oxo-3,4-dihydroisoquinoline-4-carboxylic acid
Ethyl 4-(benzenesulfonyl)-1-[(4-chlorophenyl)methyl]piperidine-4-carboxylate
1-[2-[(4-Methyl-2-oxo-1-benzopyran-7-yl)oxy]-1-oxoethyl]-4-phenyl-4-piperidinecarboxylic acid
Sarafloxacin hydrochloride
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic
(2r)-4-[(8r)-8-Methyl-2-(Trifluoromethyl)-5,6-Dihydro[1,2,4]triazolo[1,5-A]pyrazin-7(8h)-Yl]-4-Oxo-1-(2,4,5-Trifluorophenyl)butan-2-Amine
7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic acid
1-(4-fluorophenyl)-3-[(Z)-3-(4-fluorophenyl)-4-hydroxybut-2-enyl]-4-(4-hydroxyphenyl)azetidin-2-one
3-[[4-[6-(4-Morpholinyl)-3-pyridazinyl]-1-piperazinyl]-oxomethyl]-1-benzopyran-2-one
1-(4-chlorophenyl)-5-methyl-N-(phenylmethyl)-N-(thiophen-2-ylmethyl)-4-pyrazolecarboxamide
1-(4-Fluorophenyl)-3-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]pyrrolidine-2,5-dione
2-(2-furanylmethyl)-3-[[2-(3-pyridinyl)-3H-benzimidazol-5-yl]amino]-3H-isoindol-1-one
3-hydroxy-N-[[2-oxo-1-(phenylmethyl)-3-indolylidene]amino]-2-naphthalenecarboxamide
7-[[2-(3,4-dihydro-1H-isoquinolin-2-yl)-1-oxoethyl]amino]-5H-[1,3]dioxolo[4,5-f]indole-6-carboxylic acid ethyl ester
2-Furanyl-[4-[3-(4-methoxyphenyl)-7-isothiazolo[4,5-d]pyrimidinyl]-1-piperazinyl]methanone
[4-[2-(3-Chlorophenyl)-5-methyl-7-pyrazolo[1,5-a]pyrimidinyl]-1-piperazinyl]-(2-furanyl)methanone
N-[4-[[2-(4-acetamidoanilino)-5-nitro-4-pyrimidinyl]amino]phenyl]acetamide
2-[(4-ethyl-5-phenyl-1,2,4-triazol-3-yl)thio]-N-(4-phenyl-2-thiazolyl)acetamide
2-[[2-[[5-(4-Tert-butylphenyl)-2-methoxycarbonyl-3-thiophenyl]amino]-2-oxoethyl]thio]acetic acid
N-(2,5-dimethoxyphenyl)-4-[(7H-purin-6-ylthio)methyl]benzamide
N-[2-(4-acetyl-1-piperazinyl)phenyl]-2-(2,4-dichlorophenoxy)acetamide
N-{[5-(5,7-dimethyl-1,3-benzoxazol-2-yl)-2-methylphenyl]carbamothioyl}thiophene-2-carboxamide
3-(1H-indol-3-yl)-N-[4-(2-pyrimidinylsulfamoyl)phenyl]propanamide
N-(4-acetamidophenyl)-2-[5-(1-piperidinylsulfonyl)-2-thiophenyl]acetamide
[2-[(1,1-Dioxothiolan-3-yl)-methylamino]-2-oxoethyl] 2-(2-fluoroanilino)pyridine-3-carboxylate
2-(1,3-Dimethylbenzimidazol-2-ylidene)-4-(6-ethylthieno[2,3-d]pyrimidin-4-yl)sulfanyl-3-oxobutanenitrile
2-({(E)-[5-(4-fluoro-2-nitrophenyl)furan-2-yl]methylidene}amino)hexahydro-4,6-ethenocyclopropa[f]isoindole-1,3(2H,3aH)-dione
3,4-dihydro-1H-isoquinolin-2-yl-[1-(8-quinolinylsulfonyl)-2-pyrrolidinyl]methanone
Ascofuranol(1-)
A phenolate anion resulting from the deprotonation of the hydroxy group that is para- to the aldehyde group of ascofuranol. The major species at pH 7.3.
3-[(1,1-Dioxo-1,2-benzothiazol-3-yl)amino]propanoic acid [2-(cyclooctylamino)-2-oxoethyl] ester
2-[[5-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-1,3,4-oxadiazol-2-yl]thio]-N-(2,3-dimethylphenyl)acetamide
2-[[5-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-1,3,4-oxadiazol-2-yl]thio]-N-(2,4-dimethylphenyl)acetamide
6-(4-Bromophenyl)-2-(4-methoxyphenyl)-1-aza-4-azoniatricyclo[5.4.1.04,12]dodeca-2,4(12),6-triene
[(1R,2aS,8bS)-4-(benzenesulfonyl)-2-(2-pyridinylmethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-1-yl]methanol
(1S,5R)-3-(2-methoxyphenyl)sulfonyl-7-[4-(3-pyridinyl)phenyl]-3,6-diazabicyclo[3.1.1]heptane
1-[(1S)-1-(hydroxymethyl)-7-methoxy-1-methylsulfonyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-butanone
(1R,5S)-6-(2-methoxyphenyl)sulfonyl-7-(4-pyridin-4-ylphenyl)-3,6-diazabicyclo[3.1.1]heptane
(1R,5S)-6-(4-methoxyphenyl)sulfonyl-7-(4-pyridin-4-ylphenyl)-3,6-diazabicyclo[3.1.1]heptane
1-[(1R)-1-(hydroxymethyl)-7-methoxy-1-methylsulfonyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-butanone
5-{[4-({Hydroxy[(4-nitrophenyl)amino]phosphoryl}methyl)phenyl]amino}-5-oxopentanoic acid
N-[(E)-(5-chloro-2-hydroxyphenyl)methylideneamino]-4-piperidin-1-ylsulfonylbenzamide
3-(4-Methyl-thiazol-2-yl)-7-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-chromen-4-one
2,8-Ditrimethylsilyloxy-4-quinolinecarboxylic acid trimethylsilyl ester
2,6-Ditrimethylsilyloxy-4-quinolinecarboxylic acid trimethylsilyl ester
10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3,4:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
BAY-4931
BAY-4931 is a potent, covalent and selective PPARγ inverse-agonist with an IC50 of 0.17 nM[1].
MF-438
MF-438 is a potent and orally bioavailable stearoyl-CoA desaturase 1 (SCD1) inhibitor with an IC50 of 2.3 nM for rSCD1[1].
p53-MDM2-IN-1
p53-MDM2-IN-1 (Example 30) is an inhibitor of p53-MDM2/X protein interaction with an Ki value of 23.35 μM. p53-MDM2-IN-1 can be used for anti-tumor research[1].
TAK-071
TAK-071 is a novel, potent and highly selective muscarinic acetylcholine receptor 1 (M1R) positive allosteric modulator. EC50 of TAK-071 M1R agonist activities is 520 nM[1].